Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is engaged in a highly competitive and fragmented segment of sterile water, dry power-syrup products. It marked inconsistency in its top lines for the reported periods. Highly fluctuating bottom lines raises eyebrows. Based on FY25 super earnings, the issue appears fully priced. Well-informed investors may park moderate funds for long term. Read detail review...
Onyx Biotec Limited peer comparison with similar listed entities. (As on March 28, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Onyx Biotec Limited | 2.28 | 2.28 | 18.67 | 26.81 | 12.19 | 3.27 | |
| Suven Pharmaceuticals Limited | 11.80 | 11.80 | 375.82 | 83.92 | 14.64 | 2.64 | |
| JB Chemicals | 35.66 | 35.66 | 188.37 | 53.63 | 18.90 | 10.15 |
Source: All the financial information for listed industry peer mentioned above is sourced from the annual report of the relevant companies for Fiscal 2024, as available on the websites of the NSE and BSE.
Notes for peer group:
Onyx Biotec IPO Reviews, analysis and views by popular members. Read Onyx Biotec Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP